Challenges and opportunities in combining radiotherapy and immunotherapy for localized pancreatic cancer.

Combining radiotherapy and immunotherapy offers a promising approach to improve survival in localized pancreatic ductal adenocarcinoma, despite current challenges.

• Why it matters: Pancreatic ductal adenocarcinoma (PDAC) patients face poor survival due to local recurrence and metastasis, with existing treatments failing to significantly extend life, highlighting the need for novel strategies.
• What they did: The authors review preclinical and clinical evidence, proposing to reposition radiotherapy as an immunological platform and exploring optimal combinations and innovative approaches to enhance treatment efficacy.
• The result: This approach could unlock superior local and systemic disease control, paving the way for improved clinical management and survival outcomes in patients with localized PDAC.